Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy. / Larsen, Mathilde S; Bjerre, Karsten; Lykkesfeldt, Anne E; Giobbie-Hurder, Anita; Laenkholm, Anne-Vibeke; Henriksen, Katrine L; Ejlertsen, Bent; Rasmussen, Birgitte B.

In: Breast (Edinburgh, Scotland), Vol. 21, No. 5, 10.2012, p. 662-8.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Larsen, MS, Bjerre, K, Lykkesfeldt, AE, Giobbie-Hurder, A, Laenkholm, A-V, Henriksen, KL, Ejlertsen, B & Rasmussen, BB 2012, 'Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy', Breast (Edinburgh, Scotland), vol. 21, no. 5, pp. 662-8. https://doi.org/10.1016/j.breast.2012.07.005

APA

Larsen, M. S., Bjerre, K., Lykkesfeldt, A. E., Giobbie-Hurder, A., Laenkholm, A-V., Henriksen, K. L., Ejlertsen, B., & Rasmussen, B. B. (2012). Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy. Breast (Edinburgh, Scotland), 21(5), 662-8. https://doi.org/10.1016/j.breast.2012.07.005

Vancouver

Larsen MS, Bjerre K, Lykkesfeldt AE, Giobbie-Hurder A, Laenkholm A-V, Henriksen KL et al. Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy. Breast (Edinburgh, Scotland). 2012 Oct;21(5):662-8. https://doi.org/10.1016/j.breast.2012.07.005

Author

Larsen, Mathilde S ; Bjerre, Karsten ; Lykkesfeldt, Anne E ; Giobbie-Hurder, Anita ; Laenkholm, Anne-Vibeke ; Henriksen, Katrine L ; Ejlertsen, Bent ; Rasmussen, Birgitte B. / Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy. In: Breast (Edinburgh, Scotland). 2012 ; Vol. 21, No. 5. pp. 662-8.

Bibtex

@article{fd2d93006ea8434ebebb82d22ab3adff,
title = "Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy",
abstract = "The four human epidermal growth factor receptors (HER1-4) are involved in growth stimulation and may play a role in endocrine resistance. The receptors form dimers, leading to activation by mutual phosphorylation. Our purpose was to explore the role of the activated receptors (pHER1, pHER2, pHER3) in endocrine treated breast cancer in terms of co-expression and association with disease-free survival (DFS) in 1062 patients with ER-positive tumors. Furthermore, HER2 amplification was evaluated. We found positive associations between the phosphorylated receptors. pHER1 and pHER3 were co-expressed with one or two of the other activated receptors in 85% and 89% of tumors, respectively, whereas pHER2 was co-expressed with the other activated receptors in 54% of tumors. Except for HER2, which was associated with poor prognosis, none of the remaining markers were associated with DFS. However, frequent co-expression indicates a role of the other HER-family members in activation of HER2.",
keywords = "Aged, Antineoplastic Agents, Hormonal/therapeutic use, Biomarkers, Tumor/metabolism, Breast Neoplasms/drug therapy, Chemotherapy, Adjuvant, Disease-Free Survival, Double-Blind Method, ErbB Receptors/metabolism, Female, Follow-Up Studies, Humans, Immunohistochemistry, In Situ Hybridization, Fluorescence, Letrozole, Mastectomy, Middle Aged, Nitriles/therapeutic use, Phosphorylation, Receptor Protein-Tyrosine Kinases/metabolism, Receptor, ErbB-2/metabolism, Receptor, ErbB-3/metabolism, Receptor, ErbB-4, Tamoxifen/therapeutic use, Treatment Outcome, Triazoles/therapeutic use",
author = "Larsen, {Mathilde S} and Karsten Bjerre and Lykkesfeldt, {Anne E} and Anita Giobbie-Hurder and Anne-Vibeke Laenkholm and Henriksen, {Katrine L} and Bent Ejlertsen and Rasmussen, {Birgitte B}",
note = "Copyright {\textcopyright} 2012 Elsevier Ltd. All rights reserved.",
year = "2012",
month = oct,
doi = "10.1016/j.breast.2012.07.005",
language = "English",
volume = "21",
pages = "662--8",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",
number = "5",

}

RIS

TY - JOUR

T1 - Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy

AU - Larsen, Mathilde S

AU - Bjerre, Karsten

AU - Lykkesfeldt, Anne E

AU - Giobbie-Hurder, Anita

AU - Laenkholm, Anne-Vibeke

AU - Henriksen, Katrine L

AU - Ejlertsen, Bent

AU - Rasmussen, Birgitte B

N1 - Copyright © 2012 Elsevier Ltd. All rights reserved.

PY - 2012/10

Y1 - 2012/10

N2 - The four human epidermal growth factor receptors (HER1-4) are involved in growth stimulation and may play a role in endocrine resistance. The receptors form dimers, leading to activation by mutual phosphorylation. Our purpose was to explore the role of the activated receptors (pHER1, pHER2, pHER3) in endocrine treated breast cancer in terms of co-expression and association with disease-free survival (DFS) in 1062 patients with ER-positive tumors. Furthermore, HER2 amplification was evaluated. We found positive associations between the phosphorylated receptors. pHER1 and pHER3 were co-expressed with one or two of the other activated receptors in 85% and 89% of tumors, respectively, whereas pHER2 was co-expressed with the other activated receptors in 54% of tumors. Except for HER2, which was associated with poor prognosis, none of the remaining markers were associated with DFS. However, frequent co-expression indicates a role of the other HER-family members in activation of HER2.

AB - The four human epidermal growth factor receptors (HER1-4) are involved in growth stimulation and may play a role in endocrine resistance. The receptors form dimers, leading to activation by mutual phosphorylation. Our purpose was to explore the role of the activated receptors (pHER1, pHER2, pHER3) in endocrine treated breast cancer in terms of co-expression and association with disease-free survival (DFS) in 1062 patients with ER-positive tumors. Furthermore, HER2 amplification was evaluated. We found positive associations between the phosphorylated receptors. pHER1 and pHER3 were co-expressed with one or two of the other activated receptors in 85% and 89% of tumors, respectively, whereas pHER2 was co-expressed with the other activated receptors in 54% of tumors. Except for HER2, which was associated with poor prognosis, none of the remaining markers were associated with DFS. However, frequent co-expression indicates a role of the other HER-family members in activation of HER2.

KW - Aged

KW - Antineoplastic Agents, Hormonal/therapeutic use

KW - Biomarkers, Tumor/metabolism

KW - Breast Neoplasms/drug therapy

KW - Chemotherapy, Adjuvant

KW - Disease-Free Survival

KW - Double-Blind Method

KW - ErbB Receptors/metabolism

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Immunohistochemistry

KW - In Situ Hybridization, Fluorescence

KW - Letrozole

KW - Mastectomy

KW - Middle Aged

KW - Nitriles/therapeutic use

KW - Phosphorylation

KW - Receptor Protein-Tyrosine Kinases/metabolism

KW - Receptor, ErbB-2/metabolism

KW - Receptor, ErbB-3/metabolism

KW - Receptor, ErbB-4

KW - Tamoxifen/therapeutic use

KW - Treatment Outcome

KW - Triazoles/therapeutic use

U2 - 10.1016/j.breast.2012.07.005

DO - 10.1016/j.breast.2012.07.005

M3 - Journal article

C2 - 22854050

VL - 21

SP - 662

EP - 668

JO - Breast

JF - Breast

SN - 0960-9776

IS - 5

ER -

ID: 259931050